 |
 |
 |
|
 |
articles < press << main |
 |
 |
|
|
|
|
|
|
|
| date | | | | title / topic / summary | sort by topic |
|---|
|
| 09/16/2002 | | | | Nymox NicAlert™ Used in National Stop-Smoking Campaign in Switzerland
topic: Tobacco Exposure Tests
September 16, 2002: Nymox Pharmaceutical Corporation announced today that its tobacco exposure test, NicAlert™, was used in a nationwide stop-smoking campaign in Switzerland. The Swiss campaign, "let it be," is jointly run by the Swiss Federal Office of Public Health, the Swiss Association for Smoking Prevention, the Swiss League Against Cancer and the Swiss Lung Association. NicAlert™ was used to test the winners of a month-long stop-smoking contest that awarded prizes ranging from CHF 500 ($340) to CHF 5000 ($3,400) to some of the over 4,000 people who participated. |
| 09/13/2002 | | | | New Nymox AlzheimAlert™ Study Begins in Phoenix
topic: AlzheimAlert™ & Diagnosis of Alzheimer's Disease
September 13, 2002: Nymox Pharmaceutical Corporation announced today that a large new prospective study of its AlzheimAlert™ urine test has begun in Phoenix at 21st Century Neurology, a large neurology treatment and research facility. The investigation is being led by Stephen S. Flitman, M. D., the Medical Director at 21st Century Neurology. Dr. Flitman specializes in cognitive and memory disorders, focusing on clinical research and modern approaches to these illnesses. |
| 09/12/2002 | | | | Nymox Announces New Marketing Initiatives With Health4u in Switzerland
topic: Marketing
September 12, 2002: Nymox Pharmaceutical Corporation announced today that the Company is pursing marketing opportunities and initiatives for its products through its new partner, Health4u, an innovative marketing company based in Allschwil near Basel, Switzerland. Health4u is a patient-orientated marketing services company, specializing in innovative approaches to healthcare and quality of life issues. |
| 09/10/2002 | | | | Nymox Begins New NicAlert™ Study For Second-Hand Smoke
topic: Tobacco Exposure Tests
September 10, 2002: Nymox Pharmaceutical Corporation is pleased to announce that a large new prospective study of its NicAlert™ test for tobacco exposure has begun at Clinical Research Centers of Tennessee. The investigation is being led by Wayne Wells M.D. Dr. Wells is Medical Director and Chief Investigator of Clinical Research Centers of Tennessee. |
| 08/27/2002 | | | | Nymox Leads with Innovative Alzheimer's Disease Programs
topic: R&D: Alzheimer's Disease Treatments
August 27, 2002: Nymox Pharmaceutical Corporation has exciting new and innovative products and approaches to the diagnosis and treatment of Alzheimer's disease in development according to Paul Averback, MD, DABP, the CEO of Nymox. Alzheimer's disease is a dreaded terminal brain disease of the elderly. An estimated 4 million Americans and more than 15 million people around the world suffer from the disease. |
| 08/22/2002 | | | | New Nymox AlzheimAlert™ Study at State University of New York
topic: AlzheimAlert™ & Diagnosis of Alzheimer's Disease
August 22, 2002: Nymox Pharmaceutical Corporation is pleased to announce that a large new prospective study of its AlzheimAlert™urine test has begun at State University of New York. The investigation is being led by Dr. Smita Kittur, M. D., the Director of the Alzheimer's Programs at SUNY Upstate Medical Center and the Syracuse VA Medical Center. |
| 08/20/2002 | | | | New Nymox Second-Hand Smoke Study Begins for NicAlert™
topic: Tobacco Exposure Tests
August 20, 2002: Nymox Pharmaceutical Corporation is pleased to announce that a large new prospective study of its NicAlert™ test for tobacco exposure has begun at West Virginia University. The investigation is being led by Dr. Norman Montalto. |
| 08/16/2002 | | | | Second-Hand Smoke Implicated in Heart Disease and Stroke
topic: Tobacco Exposure Tests
August 16, 2002: New guidelines for the prevention of heart disease and stroke recommend no exposure to tobacco smoke, including environmental tobacco smoke (ETS), more commonly known as second-hand smoke. Nymox Pharmaceutical Corporation offers NicAlert™, a sensitive, accurate and simple-to-use test that uses urine samples to detect second-hand smoke exposure. |
| 08/15/2002 | | | | Nymox NicAlert™ Test Valuable In Employee Tobacco Cessation Programs
topic: Tobacco Exposure Tests
August 15, 2002: The Nymox Pharmaceutical Corporation's NicAlert™ test has been found "to be an invaluable part" of the innovative, on-site tobacco cessation programs run by the Wellness Council of West Virginia that promote tobacco cessation and restriction for employees at their work sites. |
| 08/02/2002 | | | | Nymox Announces Private Placement
topic: Financial
August 2, 2002: Nymox Pharmaceutical Corporation announced today private placements with existing shareholders totalling $763,000. The placements were priced at $4.00 to $4.69 per share (most recently 86,000 shares at $4.69 per share). The funds are for general corporate purposes. |
|